Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England

OBJECTIVE: The aim of this study was to investigate the cost effectiveness of nivolumab versus docetaxel in previously treated, advanced non–small-cell lung cancer (NSCLC) in England and assess how conditional reimbursement within the Cancer Drugs Fund (CDF) can be used to ensure timely patient acce...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothwell, Ben, Kiff, Christopher, Ling, Caroline, Brodtkorb, Thor-Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160043/
https://www.ncbi.nlm.nih.gov/pubmed/33332018
http://dx.doi.org/10.1007/s41669-020-00245-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160043/
https://www.ncbi.nlm.nih.gov/pubmed/33332018
http://dx.doi.org/10.1007/s41669-020-00245-4

Ejemplares similares